New radioactive therapy targets Hard-to-Treat prostate cancer
NCT ID NCT07414940
First seen Feb 20, 2026 · Last updated May 24, 2026 · Updated 13 times
Summary
This study tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug aims to find and destroy cancer cells with radiation. Researchers will check safety and tumor response, especially in men who previously benefited from a similar drug (Lutetium-PSMA).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospital
RECRUITINGLondon, WC1E 6BT, United Kingdom
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.